NLSP NLS Pharmaceutics Ltd.

Nasdaq nlspharma.com


$ 1.63 $ 0.00 (0 %)    

Friday, 17-Oct-2025 04:06:19 EDT
QQQ $ 591.58 $ 0.00 (0 %)
DIA $ 455.11 $ 0.00 (0 %)
SPY $ 652.66 $ 0.00 (0 %)
TLT $ 91.50 $ 0.00 (0 %)
GLD $ 399.40 $ 0.00 (0 %)
$ 1.63
$ 1.69
$ 1.51 x 300
$ 1.63 x 39
-- - --
$ 1.30 - $ 5.64
152,371
na
1.45M
$ 15.92
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The ...

 reported-monday-august-25-2025-nls-pharmaceutics-postpones-shareholders-meeting-on-kadimastem-merger-to-september-16-to-address-sec-feedback-and-provide-updated-information

On August 21, 2025, the board of directors of NLS Pharmaceutics Ltd. (the "Company") rescheduled the meeting date of th...

 nls-pharmas-diabetes-treatment-project-gets-fresh-funding-boost-from-us-israel-foundation

NLS Pharmaceutics Ltd. (NASDAQ:NLSP) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervo...

 why-greenbrier-shares-are-trading-higher-by-over-13-here-are-20-stocks-moving-premarket

Shares of The Greenbrier Companies, Inc. (NYSE: GBX) rose sharply in today's pre-market trading after the company posted st...

Core News & Articles

Non-opioid, multi-mechanism profile positions Mazindol as a differentiated asset in addiction therapeuticsFavorable results sup...

 whats-going-on-with-nls-pharmaceutics-shares-monday

NLS Pharmaceutics shares are trading higher on Monday after the company announced it secured up to $3 million in equity financing.

 nls-pharmaceutics-merger-with-kadimastem-aims-to-create-nasdaq-traded-biotech-powerhouse-with-therapies-highlights-diabetes-als-and-opioid-treatment-advances-signals-strong-growth-ahead-with-clean-balance-sheet

 NLS Pharmaceutics Ltd. (NASDAQ:NLSP), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therap...

 nls-pharmaceutics-in-collaboration-with-aexon-labs-announced-new-preclinical-findings-on-aex-2-for-narcolepsy-and-related-neurological-disorders

Key Preclinical Findings on AEX-2 (20 mg/kg, IP)Recent preclinical advancements have demonstrated the multi-target potential of...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION